Bixori MR tablets contains etoricoxib and thiocolchicoside.
Thiocolchicoside is a sulphurated semi-synthetic derivative of colchicoside. It is a myorelaxant, which acts as GABA-A receptor antagonist. It also has powerful convulsant activity and not to be used in seizures patients.
Etoricoxib is a selective COX-2 inhibitor. Cyclo-oxgenase-2 inhibitor plays a major role in joint inflammation and pain. It produces its pharmacological action by inhibiting COX-2. It also possesses anti-arthritic property.
- Degenerative vertebral disorder with painful spasm
- Lower back pain
- Dorsal pain
- In acute pain and gout
- In osteoarthritis
- Ankylosing spondylitis
- Chronic low back pain
- Acute gouty arthritis
The drug produces its action by inhibiting the recombinant human strychnine-sensitive glycine receptors. It also causes inhibition of human nicotine acetylcholine receptors. It produces its action as muscle relaxant and have GABA-mimetic and glycinergic actions. This produces reduce in spasticity.
It is a non steroidal anti-inflammatory drug which produces its pharmacological action by inhibiting the isoform 2 of cyclo-oxgenase which is involved in inflammatory process. It inhibits prostaglandin generation from arachidonic acid.
After oral administration it is initially not detected in the plasma. One metabolite which is active is SL18.0740. The maximum plasma concentration occurs in 1hr.
After oral administration it is well absorbed and it is bound to plasma. The volume of distribution is more for thiocolchicoside to produce pharmacological action. The metabolism of the drug is in intestine. In intestine the drug is glucuroconjugated to produce the pharmacological action.
Nearly about 75% of the drug is excreted in feces and about 20% of the drug is excreted in urine. The whole drug after administration is absorbed and not excreted as unchanged form.
After oral administration the drug is 100% absorbed in the body
About 90% of the drug is bound to plasma protein. The metabolism of the drug is through liver by CYP3A4.
The drug is excreted through urine and feces
- Hypersensitivity to thiocolchicoside
- It is not to be used in the patients with flaccid paralysis and muscular hypoptonia
- Contraindicated in patients with congenital galactosemia and fructose intolerance
- Hypersensitivity to non steroidal anti-inflammatory drug
- Peptic ulcer
- Inflammatory bowel disease
- Severe congestive heart failure
- Pregnant patients
- Patients with allergic disorders
- Renal impairment
- Cardiac diseases
- Hepatic impairment
- In geriatrics patients
- Cautiously used in epileptic patients and patients with convulsions
- Lower dose should be used in patients with diarrhea